# A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

> **NCT05559008** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 116 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Azacitidine Injection
- **DRUG:** Dasatinib
- **DRUG:** Linperlisib
- **DRUG:** Tucidinostat
- **DRUG:** SHR2554
- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT05559008
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-30
- **Primary completion:** 2024-03-26
- **Final completion:** 2026-01-26
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559008, "A Umbrella Study in R/R PTCL Guided by Molecular Subtypes". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05559008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*